What is Lifesci Capital’s Forecast for MLYS Q2 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities research analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for Mineralys Therapeutics in a research note issued on Tuesday, June 17th. Lifesci Capital analyst R. Katkhuda anticipates that the company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics’ Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($2.88) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.23.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Guggenheim set a $48.00 target price on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 14th. Jefferies Financial Group assumed coverage on Mineralys Therapeutics in a research report on Tuesday, June 10th. They issued a “hold” rating and a $15.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $32.25.

Mineralys Therapeutics Stock Down 0.4%

Shares of MLYS stock opened at $13.73 on Thursday. Mineralys Therapeutics has a 12 month low of $8.24 and a 12 month high of $18.38. The company has a market cap of $894.92 million, a PE ratio of -3.68 and a beta of -0.17. The business’s 50 day moving average is $14.84 and its two-hundred day moving average is $12.86.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MLYS. Voya Investment Management LLC bought a new stake in shares of Mineralys Therapeutics in the 1st quarter worth approximately $255,000. Strs Ohio bought a new stake in shares of Mineralys Therapeutics during the first quarter valued at approximately $359,000. Woodline Partners LP acquired a new position in shares of Mineralys Therapeutics in the first quarter valued at $757,000. Goldman Sachs Group Inc. lifted its position in Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after purchasing an additional 186,480 shares during the period. Finally, Parkman Healthcare Partners LLC bought a new position in Mineralys Therapeutics in the first quarter worth $4,668,000. 84.46% of the stock is currently owned by institutional investors.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the sale, the chief financial officer now directly owns 215,340 shares of the company’s stock, valued at $2,597,000.40. This represents a 4.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Malcom Rodman sold 55,771 shares of the business’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $15.76, for a total transaction of $878,950.96. Following the transaction, the insider now owns 116,704 shares in the company, valued at approximately $1,839,255.04. The trade was a 32.34% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 104,579 shares of company stock worth $1,534,353. Insiders own 25.56% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.